Abstract 60P
Background
Using liquid-based next generation sequencing (NGS) to detect circulating tumor DNA (ctDNA) and understanding genetic profiling has become more accessible recently. However, there is still limited prospective data in Asian breast cancer patients. This study is using Guardant360 to identify the genetic landscape of patients with recurrent breast cancer (BC) and de novo stage IV metastatic BC in an Asian population and to demonstrate genetic profile changes at disease progression.
Methods
Patients with either recurrent BC or de novo stage IV BC underwent both tissue-based NGS and liquid-based NGS before systemic therapy, and had liquid-based NGS done at PD. All patients were recruited from MacKay Memorial hospital from Jan 2020 to Dec 2021. The study was suspended in Jan 2022 due to restructuring of the sponsor’s organisation. Oncomine Comprehensive Assay was used for tissue based NGS, and Guardant360 was used for liquid based NGS.
Results
There were 44 patients (age range: 37-90 years old) recruited in the study, with 55 liquid samples (44 baseline and 11 PD samples), and 46 primary tissue samples or metastatic tissue samples in total. All the 46 tissue samples and all the 55 liquid samples were successfully sequenced. Out of the 44 liquid samples prior systemic therapy, ctDNA were detected in 84% (n=37) of the samples. Among of these 37 ctDNA positive samples, 64% of them have targetable alterations detected, including PIK3CA (31.8%, n=14), BRCA2 (20.5%, n=9), BRCA1 (9.1%, n=4), ERBB2 (4.6%, n=2), ESR1 (4.6%, n=2), FGFR2 amplification (4.6%, n=2), AKT1 (2.3%, n=1), and FGFR1 amplification (2.3%, n=1). In the study, we observed that higher percentage BRCA2/BCRA1 mutation was detected by liquid biopsy. A total of 31 patients underwent liquid and tissue NGS. We observed a high concordance in ESR1 alteration with 100%. Of the 12 patients with PIK3CA mutation detected in liquid and/or tissue, 8 were detected in both tissue and liquid, 2 detected in tissue alone and 2 detected in liquid alone.
Conclusions
Liquid-based NGS can be applied in clinical practice to identified clinically important mutations in Asian patients with recurrent breast cancer (BC) and de novo stage IV metastatic BC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
P-S. Yang.
Funding
Yonglin Foundation, Taipei, Taiwan.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
462P - Cognitive function of survivors with non-central nervous system cancer and its correlates: A community rehabilitation perspective
Presenter: Ann Kuo
Session: Poster Display
Resources:
Abstract
463P - The use of antipsychotic for managing delirium in patients with cancer
Presenter: Natasya Reina
Session: Poster Display
Resources:
Abstract
464P - The prevalence and correlates of frailty and pre-frailty in elderly patients with breast cancer: A cross-sectional study from China
Presenter: Min Xiao
Session: Poster Display
Resources:
Abstract
465P - Oncological care needs of people with mental illness: A single institution experience in Australia
Presenter: Hui Ling Yeoh
Session: Poster Display
Resources:
Abstract
466P - Identification of patient satisfaction predictors among women attending oncology daycare unit using validated survey questionnaire (PSS Tool): An institutional experience in central India
Presenter: Rajesh Patidar
Session: Poster Display
Resources:
Abstract
467P - Evaluation of the effectiveness of a cluster management model based on evidence-based concepts in oncology nutrition case management
Presenter: Li He
Session: Poster Display
Resources:
Abstract
468P - The patterns of use of Traditional Chinese Medicine (TCM) in cancer patients in Hong Kong
Presenter: Olivia L T Chan
Session: Poster Display
Resources:
Abstract
469P - The need of special care for adolescent and young adult (AYA) cancer survivors: Perspective from oncologists in India
Presenter: Nandini Menon
Session: Poster Display
Resources:
Abstract
470TiP - Randomised controlled trial to evaluate the efficacy and safety of moisturising creams with or without palm-oil-derived vitamin E concentrate in addition to urea-based cream or urea-based cream alone in Capecitabine-associated Palmar-Plantar Erythrodysesthesia (ECaPPE)
Presenter: Pei-Jye Voon
Session: Poster Display
Resources:
Abstract
471TiP - A group sequential, response-adaptive randomized double-blinded clinical trial to evaluate add-on olanzapine plus pregabalin to prevent chemotherapy-induced nausea and vomiting (CINV ) in patients belonging to low socio-economic status
Presenter: Mathan Ramasubbu
Session: Poster Display
Resources:
Abstract